Pharmaceutical

Background During China’s drug procurement process, patent infringement of originator drugs still exists. The process of stopping such infringement involves multiple government agencies that lack effective coordination.As a result, companies facing infringement must go through a lengthy and difficult process to defend their rights. This undermines the legitimate rights of Read more…

Background The development of originator drugs on average takes up to 12 years and costs more than EUR 2 billion. However, new drugs are easily copied, and the lengthy patent registration and drug regulatory processes take up the originator drug’s patent term and reduce its lifespan in the market. In Read more…